LSV Asset Management lowered its position in Ingevity Co. (NYSE:NGVT - Free Report) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 761,962 shares of the company's stock after selling 31,580 shares during the period. LSV Asset Management owned about 2.10% of Ingevity worth $31,050,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of NGVT. Wellington Management Group LLP increased its holdings in Ingevity by 5.4% in the 4th quarter. Wellington Management Group LLP now owns 2,239,970 shares of the company's stock worth $91,279,000 after acquiring an additional 115,581 shares in the last quarter. State Street Corp increased its stake in shares of Ingevity by 14.7% during the third quarter. State Street Corp now owns 1,546,957 shares of the company's stock worth $60,331,000 after purchasing an additional 198,300 shares in the last quarter. American Century Companies Inc. raised its position in shares of Ingevity by 37.7% during the 4th quarter. American Century Companies Inc. now owns 1,457,365 shares of the company's stock worth $59,388,000 after purchasing an additional 398,800 shares during the last quarter. Segall Bryant & Hamill LLC lifted its stake in Ingevity by 8.6% in the 4th quarter. Segall Bryant & Hamill LLC now owns 1,287,281 shares of the company's stock valued at $52,457,000 after buying an additional 101,866 shares in the last quarter. Finally, Royce & Associates LP boosted its holdings in Ingevity by 22.4% in the 4th quarter. Royce & Associates LP now owns 1,142,598 shares of the company's stock worth $46,561,000 after buying an additional 208,921 shares during the last quarter. 91.59% of the stock is owned by hedge funds and other institutional investors.
Ingevity Stock Up 0.5 %
Shares of Ingevity stock traded up $0.14 during trading hours on Tuesday, reaching $31.88. 249,904 shares of the company were exchanged, compared to its average volume of 274,339. The firm has a market cap of $1.16 billion, a PE ratio of -2.69 and a beta of 1.54. The stock's fifty day moving average is $41.94 and its 200 day moving average is $42.07. Ingevity Co. has a 1 year low of $28.49 and a 1 year high of $56.30. The company has a debt-to-equity ratio of 6.86, a quick ratio of 1.04 and a current ratio of 1.87.
Ingevity (NYSE:NGVT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.66. The company had revenue of $298.80 million for the quarter, compared to the consensus estimate of $297.40 million. Ingevity had a positive return on equity of 41.44% and a negative net margin of 30.60%. As a group, equities research analysts forecast that Ingevity Co. will post 4.45 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on NGVT. Wells Fargo & Company lowered their price target on Ingevity from $45.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. StockNews.com cut shares of Ingevity from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, BMO Capital Markets raised shares of Ingevity from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $62.00 to $65.00 in a research note on Wednesday, February 26th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $53.83.
Read Our Latest Analysis on NGVT
About Ingevity
(
Free Report)
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Further Reading
Before you consider Ingevity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.
While Ingevity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
